Ben Venue Consent Decree Could Be Signal on Hospira, Analyst Says

January 24, 2013
Boehringer Ingelheim subsidiary Ben Venue Laboratories has signed a consent decree to resolve a history of good manufacturing practice (GMP) slipups. The decree would let it continue making some essential drugs while a third party assesses its facilities — a provision analysts say could open the door to a similar decree for Hospira.
Drug Industry Daily